Literature DB >> 26188010

Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection.

Joseph M Volpe1, Douglas J Ward2, Laura Napolitano1, Pham Phung1, Jonathan Toma1, Owen Solberg1, Christos J Petropoulos3, Charles M Walworth1.   

Abstract

Transmitted HIV-1 exhibiting reduced susceptibility to protease and reverse transcriptase inhibitors is well documented but limited for integrase inhibitors and enfuvirtide. We describe here a case of transmitted 5 drug class-resistance in an antiretroviral (ARV)-naïve patient who was successfully treated based on the optimized selection of an active ARV drug regimen. The value of baseline resistance testing to determine an optimal ARV treatment regimen is highlighted in this case report.
© The Author(s) 2015.

Entities:  

Keywords:  enfuvirtide; integrase inhibitors; maraviroc; transmitted drug resistance; tropism

Mesh：

Substances：

Year:  2015        PMID： 26188010     DOI： 10.1177/2325957415596229

Source DB:  PubMed          Journal:  J Int Assoc Provid AIDS Care        ISSN： 2325-9574


  7 in total

1.  Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

Authors:  Philip L Tzou; Soo-Yon Rhee; Diane Descamps; Dana S Clutter; Bradley Hare; Orna Mor; Maxime Grude; Neil Parkin; Michael R Jordan; Silvia Bertagnolio; Jonathan M Schapiro; P Richard Harrigan; Anna Maria Geretti; Anne-Geneviève Marcelin; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

2.  Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.

Authors:  Carole L Wallis; Raquel V Viana; Shanmugam Saravanan; Carlos Silva de Jesus; Clement Zeh; Elias K Halvas; John W Mellors
Journal:  J Virol Methods       Date:  2016-12-16       Impact factor: 2.014

3.  Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.

Authors:  A Tostevin; E White; D Dunn; S Croxford; V Delpech; I Williams; D Asboe; A Pozniak; D Churchill; A M Geretti; D Pillay; C Sabin; A Leigh-Brown; E Smit
Journal:  HIV Med       Date:  2016-08-01       Impact factor: 3.180

4.  Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Authors:  Michael E Abram; Renee R Ram; Nicolas A Margot; Tiffany L Barnes; Kirsten L White; Christian Callebaut; Michael D Miller
Journal:  PLoS One       Date:  2017-02-17       Impact factor: 3.240

Review 5.  HIV-1 drug resistance and resistance testing.

Authors:  Dana S Clutter; Michael R Jordan; Silvia Bertagnolio; Robert W Shafer
Journal:  Infect Genet Evol       Date:  2016-08-29       Impact factor: 3.342

6.  Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.

Authors:  Vici Varghese; Benjamin A Pinsky; Darvin S Smith; Daniel Klein; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2016-04-19       Impact factor: 2.205

7.  Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.

Authors:  Timothy W Menza; Rachael Billock; Erika Samoff; Joseph J Eron; Ann M Dennis
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.